Lux Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Ophthalmology-focused Lux Biosciences Inc. joins the ranks of recently founded in-licensers that have pulled down massive A-rounds on the back of management's track record and an in-licensed prospect. Lux's lead candidate is a calcineurin inhibitor; its initial target is uveitis.
You may also be interested in...
Venture Eyes Ophthalmology--And Likes What It Sees
Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.
Ophthotech Raises $36 million, In-licenses Aptamers
Three venture capital firms funded the ophthalmology start-up with a $36 million Series A that will pay for the acquisition of two IND-stage drug candidates: the similarity to another start-up, Lux Biosciences, is startling. Can the founders of Eyetech take the Lux model and build another success for SVLS, HBM Bioventures, and Novo AS?
Ophthotech Raises $36 million, In-licenses Aptamers
Three venture capital firms funded the ophthalmology start-up with a $36 million Series A that will pay for the acquisition of two IND-stage drug candidates: the similarity to another start-up, Lux Biosciences, is startling. Can the founders of Eyetech take the Lux model and build another success for SVLS, HBM Bioventures, and Novo AS?